UnitedHealthcare Community Plan

Prior Authorization Request Form
Fax Back To: (866) 940-7328
Phone: (800) 310-6826

Specialty Medication Prior Authorization Cover Sheet

(This cover sheet should be submitted along with a Pharmacy Prior Authorization Medication Fax Request Form. Please refer to www.uhcprovider.com for medication fax request forms.)

Patient Information

Patient's Name:

Insurance ID: Date of Birth: Height: Weight:

Address: Apartment #:

City: State: Zip Code:

Phone Number: Alternate Phone: Sex: ☐ Male ☐ Female

Provider Information

Provider's Name: Provider ID Number:

Address: City: State: Zip Code:

Suite Number: Building Number:

Phone Number: Fax number:

Provider's Specialty:

Medication Information

Medication: Quantity: ICD10 Code:

Directions: Diagnosis: Refills:

Physician Signature**: Initial here if DAW:

Physician Signature**: By signing above, the physician is providing the specialty pharmacy with a prescription that can be used to facilitate the dispensing and/or coordination of delivery for the requested medication.

Medication Instructions

Has the patient been instructed on how to **Self-Administer**? ☐ Yes ☐ No

Is this medication a **New Start**? ☐ Yes ☐ No

If continuation please provide the following: Initiation Date: / / Date of Last Dose: / /

Is there documentation of positive clinical response to current therapy? ☐ Yes ☐ No

****Please attach any pertinent clinical information that would pertain to support stated diagnosis. Additional clinical information may be needed depending on your patients plan, including medication(s) previously tried and failed.**

Delivery Instructions

Note: Delivery coordination requires a "**Physician Signature**" above and complete "**Provider Information**" and "**Patient Information**"

Note: All necessary ancillary supplies are provided free of charge to the patient at the time of delivery

Ship to: Physician's Office ☐ Patient's Address ☐ Date medication is needed: / /

Medication Administered: Home Health ☐ Self-Administered ☐ LTC ☐ Physician's Office ☐

This electronic fax transmission, including any attachments contains information for or from UnitedHealthcare that may be confidential and/or privileged. The information contained in this facsimile is intended to be for the sole use of the individual(s) or entity named above. If you are not the intended recipient, be aware that any disclosure, copying, distribution or use of the contents of this information is strictly prohibited by law and will be vigorously prosecuted. If you have received this electronic fax transmission in error, please notify the sender immediately and destroy all electronic hard copies of the communications including attachments

UnitedHealthcare Community Plan

Dupixent

PRIOR AUTHORIZATION REQUEST FORM

Please complete this entire form and fax it to: **866-940-7328**. If you have questions, please call **800-310-6826.**

This form contains multiple pages. Please complete all pages to avoid a delay in our decision.

Allow at least 24 hours for review.

Section A – Member Information

First Name:	Last Name:	Member ID:
Address:		
City:	State:	ZIP Code:
Phone:	DOB:	Allergies:
Primary Insurance Information:		

Is the requested medication □ New or □ Continuation of Therapy? If continuation, list start date: ________________

Is this patient currently hospitalized? □ Yes □ No If recently discharged, list discharge date: _________________

Section B - Provider Information

First Name:		Last Name: M.D./D.O.		
Address:		City:	State:	ZIP code:
Phone:	Fax:	NPI #:	Specialty:	
Office Contact Name / Fax attention to:				

Section C - Medical Information

Medication:	**Strength:**
Directions for use:	**Quantity:**
Diagnosis (Please be specific & provide as much information as possible):	**ICD-10 CODE:**

Is this member pregnant? □ Yes □ No If yes, what is this member's due date? ________________

Section D – Previous Medication Trials

Medications	Strength	Directions	Dates of Therapy	Reason for failure / discontinuation

Section E – Additional information and Explanation of why preferred medications would not meet the patient's needs:

Please refer to the patient's PDL for a list of preferred alternatives

UnitedHealthcare Community Plan

Dupixent

PRIOR AUTHORIZATION REQUEST FORM

Member First name:	Member Last name:	Member DOB:

Clinical and Drug Specific Information

ALL REQUESTS	
□ **Yes** □ **No**	**Does the patient have one of the following diagnoses?** *(If yes, check which applies)* □ Moderate chronic atopic dermatitis □ Severe chronic atopic dermatitis □ Moderate to severe Asthma
□ **Yes** □ **No**	**Is the patient receiving Dupixent in combination with any of the following?** *(If yes, check which applies)* □ Anti-interleukin-5 therapy [e.g. Nucala (mepolizumab), Cinqair (resilizumab), Fasenra (benralizumab)] □ Anti-IgE therapy [e.g. Xolair (omalizumab)] □ Biologic medication [e.g. Enbrel (etanercept), Rituxan (rituximab), Remicade/Inflectra (infliximab)] *If yes, list rationale:*
□ **Yes** □ **No**	**Is Dupixent prescribed by one of the following?** *(If yes, check which applies)* □ Dermatologist □ Allergist □ Immunologist □ Pulmonologist
CHRONIC ATOPIC DERMATITIS	
□ **Yes** □ **No**	**Does the patient have a history of failure, contraindication, or intolerance to any of the following topical therapies?** *(If yes, check which applies and complete Section D above)* □ Medium to very-high potency topical corticosteroid [e.g., Elocon (mometasone furoate), Synalar (fluocinolone acetonide), Lidex (fluocinonide)] □ Topical calcineurin inhibitor [e.g., Elidel (pimecrolimus), Protopic (tacrolimus)]. □ Eucrisa (crisaborole)
MODERATE TO SEVERE ASTHMA *(continued on next page)*	
□ **Yes** □ **No**	**Is the patient's asthma uncontrolled or inadequately controlled as defined by at least one of the following?** *(If yes, check which applies)* □ Poor symptom control (e.g., Asthma Control Questionnaire [ACQ] score consistently greater than 1.5 or Asthma Control Test [ACT] score consistently less than 20) *List rationale:* □ Two or more bursts of systemic corticosteroids for at least 3 days each in the previous 12 months *List corticosteroid and dates:* □ Asthma-related emergency treatment (e.g., emergency room visit, hospital admission, or unscheduled physician's office visit for nebulizer or other urgent treatment) *List emergency treatment:* □ Airflow limitation (e.g., after appropriate bronchodilator withhold forced expiratory volume in 1 second [FEV1] less than 80% predicted [in the face of reduced FEV1-forced vital capacity [FVC] defined as less than the lower limit of normal]) *List rationale:* □ Patient is currently dependent on oral corticosteroids for the treatment of asthma *List oral corticosteroid:*
□ **Yes** □ **No**	**Is there submission of medical records (e.g., chart notes, laboratory values, etc.) documenting that asthma is an eosinophilic phenotype as defined by a baseline (pre-dupilumab treatment) peripheral blood eosinophil level ≥ 150 cells/μL within the past 6 weeks?** *If yes, list peripheral blood eosinophil level and date:*
□ **Yes** □ **No**	**Is the patient currently dependent on oral corticosteroids for the treatment of asthma?** *If yes, list corticosteroids:*
□ **Yes** □ **No**	**Will Dupixent be used in combination with one high dose (appropriately adjusted for age) combination inhaled corticosteroid (ICS)/long-acting beta2 agonist (LABA)?** *If yes, list combo ICS/LABA product:*

UnitedHealthcare Community Plan

Dupixent

PRIOR AUTHORIZATION REQUEST FORM

Member First name:	**Member Last name:**	**Member DOB:**

□ **Yes** □ **No**	**Will Dupixent be used in combination with one high-dose (appropriately adjusted for age) ICS product?** *If yes, list high dose ICS product:*
□ **Yes** □ **No**	**Will Dupixent be used in combination with any additional asthma controller medications? (e.g., long-acting beta2 agonist, theophylline, leukotriene receptor antagonist)** *If yes, list additional product:*
CONTINUATION OF THERAPY	
□ **Yes** □ **No**	**Does the patient have a documented positive clinical response to Dupixent as demonstrated by any of the following?** *(If yes, check which applies)* □ Reduction in the frequency of exacerbations □ Decreased utilization of rescue medications □ Increase in percent predicted FEV1 from pretreatment baseline □ Reduction in severity or frequency of asthma-related symptoms (e.g., wheezing, shortness of breath, coughing, etc.) □ Reduction in oral corticosteroid requirements *If other, list response:*

Physician Signature: ____ **Date:** __________________

Confidentiality Notice: This transmission contains confidential information belonging to the sender and UnitedHealthcare. This information is intended only for the use of UnitedHealthcare. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action involving the contents of this document is prohibited. If you have received this telecopy in error, please notify the sender immediately.